Shares of Adventrx Pharmaceuticals (ANX) plunged 58.27% to $1.06 today, the day after the biotech firm said the U.S. Food and Drug Administration has refused to approve its new lung-cancer drug Exelbine. Exelbine is a proprietary reformulation of the chemotherapy drug vinorelbine. Based on inspections of clinical trial sites, FDA reviewers were unable to verify […]